Cargando…

SGLT2 inhibitors and lower limb complications: an updated meta‐analysis

BACKGROUND: To exam the associations between the use of sodium glucose co-transporter 2 inhibitor (SGLT2i) and the risk of lower limb complications, and to analyze the associated factors. METHODS: Pubmed, Medline, Embase, the Cochrane Center Register of Controlled Trials for Studies and Clinicaltria...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chu, Zhu, Xingyun, Cai, Xiaoling, Yang, Wenjia, Lv, Fang, Nie, Lin, Ji, Linong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082772/
https://www.ncbi.nlm.nih.gov/pubmed/33910574
http://dx.doi.org/10.1186/s12933-021-01276-9
_version_ 1783685903603990528
author Lin, Chu
Zhu, Xingyun
Cai, Xiaoling
Yang, Wenjia
Lv, Fang
Nie, Lin
Ji, Linong
author_facet Lin, Chu
Zhu, Xingyun
Cai, Xiaoling
Yang, Wenjia
Lv, Fang
Nie, Lin
Ji, Linong
author_sort Lin, Chu
collection PubMed
description BACKGROUND: To exam the associations between the use of sodium glucose co-transporter 2 inhibitor (SGLT2i) and the risk of lower limb complications, and to analyze the associated factors. METHODS: Pubmed, Medline, Embase, the Cochrane Center Register of Controlled Trials for Studies and Clinicaltrial.gov were searched from the inception to November 2020. Randomized controlled trials of SGLT2i conducted in population containing diabetic patients with reports of amputation, peripheral arterial disease (PAD) and diabetic foot (DF) events were included. Random-effect model, fixed-effect model and meta-regression analysis were accordingly used. RESULT: The numbers of SGLT2i users versus non-SGLT2i users in the analyses of amputation, PAD and DF were 40,925/33,414, 36,446/28,685 and 31,907/25,570 respectively. Compared with non-SGLT2i users, the risks of amputation and PAD were slightly increased in patients with canagliflozin treatment (amputation: OR = 1.60, 95% CI 1.04 to 2.46; PAD: OR = 1.53, 95 % CI 1.14 to 2.05). Meta-regression analyses indicated that greater weight reduction in SGLT2i users was significantly associated with the increased risks of amputation (β = − 0.461, 95% CI − 0.726 to − 0.197), PAD (β = − 0.359, 95% CI − 0.545 to − 0.172) and DF (β = − 0.476, 95% CI − 0.836 to − 0.116). Lower baseline diastolic blood pressure (β = − 0.528, 95% CI − 0.852 to − 0.205), more systolic blood pressure reduction (β = − 0.207, 95% CI − 0.390 to − 0.023) and more diastolic blood pressure reduction (β = − 0.312, 95% CI − 0.610 to − 0.015) were significantly associated with the increased risks of amputation, PAD and DF respectively in patients with SGLT2i treatment. CONCLUSIONS: The risks of amputation and PAD were slightly increased in patients with canagliflozin treatment. Reductions in body weight and blood pressure were associated with lower limb complications in patients with SGLT2i treatment.
format Online
Article
Text
id pubmed-8082772
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80827722021-04-29 SGLT2 inhibitors and lower limb complications: an updated meta‐analysis Lin, Chu Zhu, Xingyun Cai, Xiaoling Yang, Wenjia Lv, Fang Nie, Lin Ji, Linong Cardiovasc Diabetol Original Investigation BACKGROUND: To exam the associations between the use of sodium glucose co-transporter 2 inhibitor (SGLT2i) and the risk of lower limb complications, and to analyze the associated factors. METHODS: Pubmed, Medline, Embase, the Cochrane Center Register of Controlled Trials for Studies and Clinicaltrial.gov were searched from the inception to November 2020. Randomized controlled trials of SGLT2i conducted in population containing diabetic patients with reports of amputation, peripheral arterial disease (PAD) and diabetic foot (DF) events were included. Random-effect model, fixed-effect model and meta-regression analysis were accordingly used. RESULT: The numbers of SGLT2i users versus non-SGLT2i users in the analyses of amputation, PAD and DF were 40,925/33,414, 36,446/28,685 and 31,907/25,570 respectively. Compared with non-SGLT2i users, the risks of amputation and PAD were slightly increased in patients with canagliflozin treatment (amputation: OR = 1.60, 95% CI 1.04 to 2.46; PAD: OR = 1.53, 95 % CI 1.14 to 2.05). Meta-regression analyses indicated that greater weight reduction in SGLT2i users was significantly associated with the increased risks of amputation (β = − 0.461, 95% CI − 0.726 to − 0.197), PAD (β = − 0.359, 95% CI − 0.545 to − 0.172) and DF (β = − 0.476, 95% CI − 0.836 to − 0.116). Lower baseline diastolic blood pressure (β = − 0.528, 95% CI − 0.852 to − 0.205), more systolic blood pressure reduction (β = − 0.207, 95% CI − 0.390 to − 0.023) and more diastolic blood pressure reduction (β = − 0.312, 95% CI − 0.610 to − 0.015) were significantly associated with the increased risks of amputation, PAD and DF respectively in patients with SGLT2i treatment. CONCLUSIONS: The risks of amputation and PAD were slightly increased in patients with canagliflozin treatment. Reductions in body weight and blood pressure were associated with lower limb complications in patients with SGLT2i treatment. BioMed Central 2021-04-28 /pmc/articles/PMC8082772/ /pubmed/33910574 http://dx.doi.org/10.1186/s12933-021-01276-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Original Investigation
Lin, Chu
Zhu, Xingyun
Cai, Xiaoling
Yang, Wenjia
Lv, Fang
Nie, Lin
Ji, Linong
SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
title SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
title_full SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
title_fullStr SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
title_full_unstemmed SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
title_short SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
title_sort sglt2 inhibitors and lower limb complications: an updated meta‐analysis
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082772/
https://www.ncbi.nlm.nih.gov/pubmed/33910574
http://dx.doi.org/10.1186/s12933-021-01276-9
work_keys_str_mv AT linchu sglt2inhibitorsandlowerlimbcomplicationsanupdatedmetaanalysis
AT zhuxingyun sglt2inhibitorsandlowerlimbcomplicationsanupdatedmetaanalysis
AT caixiaoling sglt2inhibitorsandlowerlimbcomplicationsanupdatedmetaanalysis
AT yangwenjia sglt2inhibitorsandlowerlimbcomplicationsanupdatedmetaanalysis
AT lvfang sglt2inhibitorsandlowerlimbcomplicationsanupdatedmetaanalysis
AT nielin sglt2inhibitorsandlowerlimbcomplicationsanupdatedmetaanalysis
AT jilinong sglt2inhibitorsandlowerlimbcomplicationsanupdatedmetaanalysis